News
-
Phase III Data Show Greater Compliance Across Demographic Groups With Agile Therapeutics' Contraceptive Patch Compared To An Oral Contraceptive
11/1/2012
Agile Therapeutics presented findings from a phase III pivotal trial of AG200-15, Agile's investigational once-weekly combination contraceptive patch containing ethinyl estradiol (EE) in combination with levonorgestrel (LNG).
-
Abbott Presents Positive Results From Phase 2 "Pilot" Study Of An Interferon-Free Combination Regimen For The Treatment Of Hepatitis C
4/19/2012
Abbott (NYSE: ABT) and Enanta Pharmaceuticals announced complete data from the study known as "Pilot" – Abbott's initial interferon-free study of its direct-acting antiviral agents for the treatment of hepatitis C (HCV) – showing that 91 percent of genotype 1 infected, treatment-naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks (SVR24).
-
Abbott To Present Positive Phase 2 Results From Multiple Interferon-Free Studies Of Combination Regimens For The Treatment Of Hepatitis C
4/9/2012
Abbott (NYSE: ABT) will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress™ 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain.
-
Many Cancer Rates Continue To Decline
4/2/2012
Death rates from all cancers combined for men, women, and children continued to decrease in the United States between 2004 and 2008.
-
Lilly Steps Up Efforts To Improve Diversity In Clinical Trials
9/26/2011
Racial and ethnic minorities are more likely to develop cancer and die from it than the general U.S. population.
-
PAREXEL Achieves 100th Asian Ethnobridging Study Milestone
7/25/2011
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced today that it has achieved a significant milestone by completing its 100th Asian ethnobridging study, which is designed to help biopharmaceutical companies accelerate development for the Asia/Pacific market.